Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: ctDNA in Stage IIA Colon Cancer
NCT04068103Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Dec 2019
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of oxaliplatin, fluorouracil, capecitabine in colon cancer, sponsored by NRG Oncology. Started Dec 2019; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04068103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068103.